Merck & Co., Inc. (MRK)
| Market Cap | 206.88B |
| Revenue (ttm) | 63.92B |
| Net Income (ttm) | 17.43B |
| Shares Out | 2.51B |
| EPS (ttm) | 6.88 |
| PE Ratio | 11.98 |
| Forward PE | 9.19 |
| Dividend | $3.24 (3.93%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 16,051,013 |
| Open | 82.06 |
| Previous Close | 81.81 |
| Day's Range | 81.89 - 82.81 |
| 52-Week Range | 73.31 - 129.93 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 113.71 (+38.01%) |
| Earnings Date | Jul 29, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $113.71, which is an increase of 38.01% from the latest price.
News
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori...
Top 15 High-Growth Dividend Stocks For July 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...
Top 10 High-Yield Dividend Stocks For July 2025
My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performi...
Dividend Yield Theory Says Merck Is A Buy
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expira...
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant s...
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipelin...
Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines, is now recommending the respiratory syncytial virus (RSV) vaccine for infants...
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial vir...
ACIP recommends Merck's RSV shot for infants under 8 months old
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the CDC.
US CDC panel votes in favor of Merck's RSV antibody drug
An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, who...
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention.
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (...
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan...
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...
2 Wonderful Dividends Practically Giving Themselves Away
High quality doesn't have to come at a high price. I highlight 2 moat-worthy stocks that are trading far below historical valuations. Both carry strong operating fundamentals and pay well-covered divi...
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYT...